Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics shares are trading lower after the company announced topline results from its Phase 2 clinical trial of barzolvolimab.
July 30, 2024 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Celldex Therapeutics shares are trading lower after the company announced topline results from its Phase 2 clinical trial of barzolvolimab.
The announcement of topline results from a clinical trial is a significant event for biotech companies. The market's negative reaction suggests that the results may not have met investor expectations, leading to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100